The capability for erythropoietin-induced differentiation of TF-1 erythroleukemia cells with IDH2R140Q overexpression is restored after AGI-6780 treatment in vitro, and the same effect was seen in patient-derived primary IDH2-mutant AML blood and bone marrow samples cultured ex vivo (72). Here, IDH2 is linked to acute myeloid leukemia.